Daniel Bending

Navigating dose escalation and selection is a crucial stage in early development to set up ADC performance for success under Project Optimus guidelines

Don’t miss this Eli Lilly-led workshop to delve into all things ADC clinical pharmacology across quantitative systems pharmacology and clinical utility index approaches to optimise your ADC dose selection

Workshop highlights include:

• Utilising quantitative systems pharmacology to investigate ADC preclinical PK/PD characterisation
• Leveraging clinical utility index approach to assess the benefit-risk profiles of ADCs
• Understanding ADC-specific clinical pharmacology considerations and assessing lessons learnt from ADC dose capping